GlassScriptPhysician profile
Michelle Gauthier
NPI 1265489264
$8,735.16
in general payments reported to CMS, 2019-2025
42 companies · $1,003 in 2025
The $1,003 reported for 2025 was more than what 86% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,163 · 2020: $301 · 2021: $790 · 2022: $1,767 · 2023: $2,432 · 2024: $1,279 · 2025: $1,003.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,541 · Education: $173.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,540.76 |
| Education | $173.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,522.37 | 2021-2025 | |
| Novo Nordisk INC | $878.00 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $801.30 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Astellas Pharma US INC | $795.92 | 2019-2025 | Veozah, Myrbetriq |
| Pfizer INC. | $629.31 | 2019-2025 | |
| Lilly USA, LLC | $470.35 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Daiichi Sankyo INC. | $424.82 | 2022-2024 | Injectafer |
| Glaxosmithkline, LLC. | $361.28 | 2019-2025 | Shingrix, Arexvy, Nucala |
| Boehringer Ingelheim Pharmaceuticals, INC. | $300.92 | 2019-2024 | Jardiance |
| Dentsply Sirona INC | $256.72 | 2023-2024 | Implant Dentistry |
| Janssen Pharmaceuticals, INC | $245.76 | 2019-2024 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $200.78 | 2019-2025 | Eliquis, Camzyos |
| Idorsia Pharmaceuticals US INC | $182.39 | 2023 | Quviviq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $173.65 | 2019-2023 | Xifaxan |
| Amgen INC. | $169.92 | 2019-2025 | Evenity, Prolia, Repatha |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ibsa Pharma INC. | $156.79 | 2019-2024 | Tirosint, Licart, Flector |
| Nestle Healthcare Nutrition INC. | $117.90 | 2021-2023 | |
| Exact Sciences Corporation | $110.58 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Abbott Laboratories | $101.82 | 2022-2023 | Freestyle Libre 3 |
| Dynavax Technologies Corporation | $85.57 | 2022-2025 | Heplisav-B |
| Scilex Pharmaceuticals INC. | $69.30 | 2019-2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $60.07 | 2022 | |
| Merck Sharp & Dohme LLC | $57.77 | 2019-2025 | Gardasil 9, Vaxneuvance, Vaxelis |
| Aimmune Therapeutics, INC. | $56.18 | 2024-2025 | Zenpep |
| Phathom Pharmaceuticals, INC. | $55.80 | 2025 | Voquezna |
| Sanofi Pasteur INC. | $49.69 | 2019-2022 | |
| Lundbeck LLC | $42.54 | 2023-2024 | Vyepti, Rexulti |
| Ironshore Pharmaceuticals INC. | $39.33 | 2019 | |
| Supernus Pharmaceuticals, INC. | $37.38 | 2022 | |
| Allergan, INC. | $35.60 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $31.88 | 2019 | |
| Taiho Oncology, INC. | $28.75 | 2024 | |
| Vanda Pharmaceuticals INC. | $23.97 | 2025 | Fanapt |
| Boston Scientific Corporation | $22.06 | 2025 | Watchman Access System |
| Bausch Health US, LLC | $20.30 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $20.10 | 2022 | |
| Dexcom, INC. | $19.22 | 2024 | Dexcom G6 Transmitter |
| Takeda Pharmaceuticals U.S.A., INC. | $18.27 | 2020 | |
| Axsome Therapeutics, INC. | $17.37 | 2025 | Auvelity |
| Horizon Therapeutics Plc | $14.71 | 2019 | |
| Roche Diabetes Care, INC. | $14.53 | 2019 | |
| Alexion Pharmaceuticals, INC. | $14.19 | 2023 | Strensiq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Gauthier listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.